Eli Lilly to Seek FDA Nod for Retatrutide After 22.6% Weight Loss in Phase 3
Updated
Updated · Forbes · Jul 23
Eli Lilly to Seek FDA Nod for Retatrutide After 22.6% Weight Loss in Phase 3
3 articles · Updated · Forbes · Jul 23
Summary
Q1 2027 is when Eli Lilly plans to file for FDA approval of Retatrutide after two phase 3 trials showed strong weight-loss results in obesity and diabetes patients.
22.6% average weight loss—55.8 pounds—was recorded after 80 weeks in adults with severe obesity, while adults with obesity and diabetes lost 20.8%, or about 49.6 pounds.
Retatrutide also showed fewer major adverse cardiovascular events than anticipated, and its three-hormone approach—targeting GLP-1, GIP and glucagon—could make it the most potent obesity drug yet.
Lilly is pushing the candidate as it tries to extend its lead over Novo Nordisk in the GLP-1 market, where analysts see retatrutide generating $3.8 billion in 2030 sales and as much as $15.6 billion by 2031.
Amid lawsuits and looming price wars, will the pharma giant battle make these blockbuster weight-loss drugs more affordable for average patients?
Could the powerful mechanism of the new 'king' of weight-loss drugs hide unforeseen long-term health risks for its future users?
With a black market already booming, how can regulators protect consumers from dangerous fakes of this highly anticipated new drug?
Retatrutide’s 28.7% Weight Loss Efficacy: Regulatory Path, Market Dynamics, and Patient Access Challenges
Overview
Retatrutide is advancing rapidly toward regulatory approval, with Eli Lilly focusing on high-risk patients such as those with diabetes and heart disease—key groups for both regulators and payers. The presentation of pivotal Phase 3 results at the ADA meeting highlights its advanced clinical stage and signals a strong move toward market entry. As the global anti-obesity drug market grows, especially with new launches like Wegovy in India, retatrutide is well-positioned to capture significant commercial opportunities. Eli Lilly’s strategic approach and robust evidence base support retatrutide’s potential to become a leading option in the expanding anti-obesity market.